Navigation Links
Onyx Pharmaceuticals to Present at the Canaccord Genuity 30th Annual Growth Conference
Date:8/3/2010

EMERYVILLE, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Canaccord Genuity 30th Annual Growth Conference on Tuesday, August 10, 2010 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through August 24, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 30, 2016 According ... Biometrics Market by Technology (Single-factor (Fingerprint, Face, ... Application (Workforce Management), End User (Hospitals, Healthcare ... by MarketsandMarkets, the market is projected to ... USD 1,182.6 Million by 2016, at a ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
(Date:5/31/2016)... Switzerland (PRWEB) , ... May 31, 2016 , ... The ... this model in their laboratories as well. However, laboratories have different challenges compared to ... benefits of lean operations in the lab, METTLER TOLEDO has developed the Lean ...
(Date:5/31/2016)... ... 2016 , ... Spectrum Aquatics has launched a brand new ADA pool lift, ... with the user in mind. , “Over the last two years our key customers ... 400 lbs lift is a necessary requirement for certain facilities with specific needs,” said ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
Breaking Medicine News(10 mins):